AITP
MCID: THR100
MIFTS: 60

Thrombocytopenic Purpura, Autoimmune (AITP)

Categories: Blood diseases, Bone diseases, Immune diseases, Rare diseases

Aliases & Classifications for Thrombocytopenic Purpura, Autoimmune

MalaCards integrated aliases for Thrombocytopenic Purpura, Autoimmune:

Name: Thrombocytopenic Purpura, Autoimmune 56 74 13
Idiopathic Thrombocytopenic Purpura 56 12 74 52 15 39 32
Autoimmune Thrombocytopenic Purpura 12 52 15 17
Immune Thrombocytopenic Purpura 56 12 58 71
Immune Thrombocytopenia 58 36 62
Itp 56 52 58
Thrombocytopenia Due to Platelet Alloimmunization 71
Purpura, Thrombocytopenic, Idiopathic 43
Immune Thrombocytopenic Purpura; Itp 56
Thrombocytopenic Purpura Autoimmune 52
Purpura Thrombocytopenic Idiopathic 54
Primary Thrombocytopenic Purpura 12
Ideopath Thrombocytopenic Pur 12
Autoimmune Thrombocytopenia 71
Idiopathic Purpura 12
Werlhof's Disease 12
Aitp 56

Characteristics:

Orphanet epidemiological data:

58
immune thrombocytopenia
Inheritance: Not applicable; Prevalence: 1-5/10000 (Europe),1-9/100000 (France); Age of onset: All ages;

OMIM:

56
Inheritance:
autosomal dominant form


HPO:

31
thrombocytopenic purpura, autoimmune:
Inheritance autosomal dominant inheritance


Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

Disease Ontology 12 DOID:8924
OMIM 56 188030
KEGG 36 H01240
ICD9CM 34 287.31
MeSH 43 D016553
NCIt 49 C3446
SNOMED-CT 67 32273002
ICD10 32 D69.3
MESH via Orphanet 44 D016553
ICD10 via Orphanet 33 D69.3
UMLS via Orphanet 72 C0398650
Orphanet 58 ORPHA3002
MedGen 41 C0398650
UMLS 71 C0242584 C0272286 C0398650

Summaries for Thrombocytopenic Purpura, Autoimmune

KEGG : 36 Immune thrombocytopenic purpura (ITP) is an acquired autoimmune disorder, and the most common cause of isolated thrombocytopenia in children. Destruction of autoantibody-sensitized platelets by Fc[gamma]R-bearing phagocytic cells in the reticuloendothelial system plays an important role. ITP is diagnosed clinically, based upon onset of thrombocytopenia in the absence of other hematologic abnormalities, or other causes of low platelets, and with a characteristic blood smear. While around 50% of typical childhood acute ITP is preceded by a viral or bacterial infection and commonly resolves within weeks to months without treatment, fewer adult cases are acute and self-resolving. Typical adult primary ITP is very similar clinically to chronic pediatric ITP. Intravenous immunoglobulin (IVIg) treatment and splenectomy (removal of the platelet-destructing organ) are effective treatment options. It has been reported that the activating FCGR2C-ORF genotype predisposes to ITP by altering the balance of activating and inhibitory Fc[gamma]R on immune cells.

MalaCards based summary : Thrombocytopenic Purpura, Autoimmune, also known as idiopathic thrombocytopenic purpura, is related to thrombocytopenia due to platelet alloimmunization and thrombocytosis. An important gene associated with Thrombocytopenic Purpura, Autoimmune is THPO (Thrombopoietin), and among its related pathways/superpathways are Phagosome and Osteoclast differentiation. The drugs Sirolimus and Tacrolimus have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and spleen, and related phenotypes are thrombocytopenia and thromboembolism

Disease Ontology : 12 A primary thrombocytopenia that involves relatively few platelets in blood as a result of autoantibodies.

NIH Rare Diseases : 52 Idiopathic thrombocytopenic purpura (ITP) is a bleeding disorder characterized by too few platelets in the blood. This is because platelets are being destroyed by the immune system . Symptoms may include bruising, nosebleed or bleeding in the mouth, bleeding into the skin, and abnormally heavy menstruation . With treatment, the chance of remission (a symptom-free period) is good. Rarely, ITP may become a chronic ailment in adults and reappear, even after remission.

OMIM : 56 Autoimmune thrombocytopenic purpura is characterized by a low platelet count, normal bone marrow, and the absence of other causes of thrombocytopenia. It is principally a disorder of increased platelet destruction mediated by autoantibodies to platelet-membrane antigens (George et al., 1994). (188030)

PubMed Health : 62 About immune thrombocytopenia: Immune thrombocytopenia (THROM-bo-si-toe-PE-ne-ah), or ITP, is a bleeding disorder. In ITP, the blood doesn't clot as it should. This is due to a low number of blood cell fragments called platelets (PLATE-lets) or thrombocytes (THROM-bo-sites). Platelets are made in your bone marrow along with other kinds of blood cells. They stick together (clot) to seal small cuts or breaks on blood vessel walls and stop bleeding.

Wikipedia : 74 Immune thrombocytopenia purpura (ITP), also known as idiopathic thrombocytopenic purpura, is a type of... more...

Related Diseases for Thrombocytopenic Purpura, Autoimmune

Diseases related to Thrombocytopenic Purpura, Autoimmune via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 884)
# Related Disease Score Top Affiliating Genes
1 thrombocytopenia due to platelet alloimmunization 31.9 THPO SELP MPL ITGB3 ITGA2B ICOSLG
2 thrombocytosis 31.1 THPO SELP MPL IL11
3 purpura 31.0 THPO MPL ITGB3 ITGA2B GP1BA CD40LG
4 anemia, autoimmune hemolytic 31.0 LRBA ICOSLG CD40LG
5 acquired thrombocytopenia 30.8 THPO MPL ITGB3 ITGA2B IL11 GP1BA
6 thrombasthenia 30.7 SELP ITGB3 ITGA2B GP1BA
7 hemoglobinuria 30.7 THPO SELP MPL
8 thrombocytopenia 3 30.7 THPO MPL
9 evans' syndrome 30.7 THPO MPL LRBA CD40LG
10 splenic sequestration 30.6 THPO MPL CD40LG
11 neutropenia 30.6 THPO MPL IL11 IFNA2 CD40LG
12 sarcoidosis 1 30.6 SELP IL18 ICOSLG CD40LG
13 hemolytic anemia 30.5 RHD LRBA IFNA2 CD40LG
14 myh-9 related disease 30.4 MPL GP1BA
15 fetal and neonatal alloimmune thrombocytopenia 30.4 ITGB3 ITGA2B GP1BA
16 polycythemia vera 30.4 THPO SELP MPL ITGB3 IFNA2
17 cryoglobulinemia, familial mixed 30.4 IFNA2 CD40LG
18 portal vein thrombosis 30.4 SELP MPL IFNA2 CD40LG
19 fournier gangrene 30.3 F8 CD40LG
20 thrombotic thrombocytopenic purpura 30.3 SELP ITGB3 CD40LG
21 pulmonary embolism 30.3 GP6 GP1BA F8 CD40LG
22 common cold 30.2 SELP IFNA2 ICOSLG
23 thrombophlebitis 30.2 SELP F8 CD40LG
24 myelofibrosis 30.2 THPO SELP MPL IFNA2 CD40LG
25 herpes zoster 30.2 IFNA2 ICOSLG CD40LG
26 von willebrand's disease 30.2 SELP ITGB3 GP6 GP1BA F8
27 coronary thrombosis 30.1 SELP ITGB3 ITGA2B GP6 GP1BA
28 hemorrhagic disease 30.1 ITGA2B GP6 GP1BA F8 CD40LG
29 aplastic anemia 30.1 THPO MPL ITGB3 ITGA2B IL18 IL11
30 dengue disease 30.1 THPO IL11 ICOSLG CD40LG
31 arteriosclerosis 30.0 SELP ITGB3 ITGA2B IL18 GP1BA
32 glanzmann thrombasthenia 30.0 SELP ITGB3 ITGA2B GP1BA F8
33 leukemia, acute myeloid 30.0 THPO MPL ITGB3 ITGA2B ICOSLG DNMT3B
34 thrombophilia 30.0 SELP ITGB3 F8 CD40LG
35 dermatitis, atopic 29.9 SELP IL18 ICOSLG GATA3
36 leukemia, chronic myeloid 29.9 THPO SELP MPL ITGB3 IL11 IFNA2
37 x-linked recessive disease 29.8 ICOSLG F8 CD40LG
38 myeloproliferative neoplasm 29.8 THPO SELP MPL ITGB3 IFNA2
39 lymphoma, mucosa-associated lymphoid type 29.7 S100A8 ICOSLG CD40LG
40 myocardial infarction 29.6 SELP ITGB3 ITGA2B IL18 GP6 GP1BA
41 cerebrovascular disease 29.6 SELP ITGB3 ITGA2B GP1BA F8 CD40LG
42 thrombosis 29.6 SELP MPL ITGB3 ITGA2B GP6 GP1BA
43 essential thrombocythemia 29.5 THPO SELP MPL ITGB3 ITGA2B IL11
44 systemic lupus erythematosus 29.4 SELP S100A8 IL18 IFNA2 ICOSLG GATA3
45 bernard-soulier syndrome 29.4 THPO SELP ITGB3 ITGA2B GP6 GP5
46 primary thrombocytopenia 29.4 THPO RHD MPL ITGB3 ITGA2B ICOSLG
47 inflammatory bowel disease 29.3 SELP S100A8 LRBA IL18 IL11 ICOSLG
48 vascular disease 29.3 SELP ITGB3 ITGA2B IL18 GP1BA F8
49 gray platelet syndrome 29.2 THPO SELP ITGA2B GP6 GP5 GP1BA
50 thrombocytopenia 28.7 THPO SELP RHD MPL ITGB3 ITGA2B

Graphical network of the top 20 diseases related to Thrombocytopenic Purpura, Autoimmune:



Diseases related to Thrombocytopenic Purpura, Autoimmune

Symptoms & Phenotypes for Thrombocytopenic Purpura, Autoimmune

Human phenotypes related to Thrombocytopenic Purpura, Autoimmune:

58 31 (show all 12)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 thrombocytopenia 58 31 hallmark (90%) Very frequent (99-80%) HP:0001873
2 thromboembolism 58 31 hallmark (90%) Very frequent (99-80%) HP:0001907
3 petechiae 58 31 frequent (33%) Frequent (79-30%) HP:0000967
4 arterial thrombosis 58 31 frequent (33%) Frequent (79-30%) HP:0004420
5 gingival bleeding 58 31 occasional (7.5%) Occasional (29-5%) HP:0000225
6 gastrointestinal hemorrhage 58 31 occasional (7.5%) Occasional (29-5%) HP:0002239
7 epistaxis 58 31 occasional (7.5%) Occasional (29-5%) HP:0000421
8 bruising susceptibility 58 31 occasional (7.5%) Occasional (29-5%) HP:0000978
9 cerebral hemorrhage 58 31 very rare (1%) Very rare (<4-1%) HP:0001342
10 purpura 58 Frequent (79-30%)
11 abnormal bleeding 31 HP:0001892
12 platelet antibody positive 31 HP:0003454

Symptoms via clinical synopsis from OMIM:

56
Heme:
thrombocytopenia
bleeding diathesis

Lab:
platelet antibody

Clinical features from OMIM:

188030

GenomeRNAi Phenotypes related to Thrombocytopenic Purpura, Autoimmune according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 9.58 ITGB3
2 Decreased viability GR00055-A-2 9.58 ITGB3
3 Decreased viability GR00055-A-3 9.58 ITGB3
4 Decreased viability GR00106-A-0 9.58 MPL
5 Decreased viability GR00221-A-2 9.58 ITGB3
6 Decreased viability GR00221-A-4 9.58 ITGB3
7 Decreased viability GR00240-S-1 9.58 CD40LG MPL
8 Decreased viability GR00249-S 9.58 ITGB3
9 Decreased viability GR00386-A-1 9.58 F8 GP1BA ICOSLG ITGA2B RHD SELP
10 Decreased viability GR00402-S-2 9.58 IL11 THPO

MGI Mouse Phenotypes related to Thrombocytopenic Purpura, Autoimmune:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10 CD40LG DNMT3B F8 GATA3 GP1BA GP6
2 homeostasis/metabolism MP:0005376 9.83 CD40LG DNMT3B F8 GATA3 GP1BA GP5
3 immune system MP:0005387 9.4 CD40LG DNMT3B F8 GATA3 GP6 IL18

Drugs & Therapeutics for Thrombocytopenic Purpura, Autoimmune

PubMed Health treatment related to Thrombocytopenic Purpura, Autoimmune: 62

Treatment for immune thrombocytopenia (ITP) is based on how much and how often you're bleeding and your platelet count. Adults who have mild ITP may not need any treatment , other than watching their symptoms and platelet counts. Adults who have ITP with very low platelet counts or bleeding problems often are treated. The acute (short-term) type of ITP that occurs in children often goes away within a few weeks or months. Children who have bleeding symptoms, other than merely bruising (purpura ), usually are treated. Children who have mild ITP may not need treatment other than monitoring and followup to make sure their platelet counts return to normal.

Drugs for Thrombocytopenic Purpura, Autoimmune (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 186)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030 46835353
2
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
3
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
4
Dexlansoprazole Approved, Investigational Phase 4 103577-45-3, 138530-94-6 9578005
5
Morphine Approved, Investigational Phase 4 57-27-2 5288826
6
Hydroxychloroquine Approved Phase 4 118-42-3 3652
7
Vincristine Approved, Investigational Phase 4 57-22-7, 2068-78-2 5978
8
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
9
Clarithromycin Approved Phase 4 81103-11-9 84029
10
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
11
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
12
glycyrrhizin Approved, Experimental Phase 4 1405-86-3 3495
13
alemtuzumab Approved, Investigational Phase 4 216503-57-0
14
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
15
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
16
Colchicine Approved Phase 4 64-86-8 2833 6167
17
Ibuprofen Approved Phase 4 15687-27-1 3672
18
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
19
Calcitriol Approved, Nutraceutical Phase 4 32222-06-3 5280453 134070
20
Caffeic acid Experimental, Investigational Phase 4 501-16-6, 331-39-5 1549111
21
Enoxolone Investigational Phase 4 471-53-4 18526330
22 Antibiotics, Antitubercular Phase 4
23 Proton Pump Inhibitors Phase 4
24 Anti-Bacterial Agents Phase 4
25 Antacids Phase 4
26 Anti-Ulcer Agents Phase 4
27 Antiprotozoal Agents Phase 4
28 Antiparasitic Agents Phase 4
29 Antioxidants Phase 4
30 Tubulin Modulators Phase 4
31 Antimitotic Agents Phase 4
32 Antimalarials Phase 4
33 Antirheumatic Agents Phase 4
34 Immunosuppressive Agents Phase 4
35 Dermatologic Agents Phase 4
36 Antifungal Agents Phase 4
37 Cytochrome P-450 Enzyme Inhibitors Phase 4
38 Cytochrome P-450 CYP3A Inhibitors Phase 4
39 Cyclosporins Phase 4
40 Calcineurin Inhibitors Phase 4
41 Antilymphocyte Serum Phase 4
42 Tin Fluorides Phase 4
43 Pharmaceutical Solutions Phase 4
44 Antineoplastic Agents, Immunological Phase 4
45 Calcium, Dietary Phase 4
46 Vitamins Phase 4
47 Calciferol Phase 4
48 Trace Elements Phase 4
49 Micronutrients Phase 4
50 Vasoconstrictor Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 358)
# Name Status NCT ID Phase Drugs
1 A Phase IV, Open-label, Prospective, Multicenter Study of the Efficacy and Safety of Recombinant Human Thrombopoietin Injection (rHuTPO, TPIAO)on Platelet Engraftment in Allogeneic Hematopoietic Stem Cell Transplantation in China Unknown status NCT01379391 Phase 4 Recombinant Human Thrombopoietin (rHTPO)
2 Tacrolimus Treatment for Refractory Pure Red Cell Aplasia, a Prospective Study Unknown status NCT03540472 Phase 4 tacrolimus
3 Sirolimus Treatment for Refractory Pure Red Cell Aplasia, a Prospective Study Unknown status NCT03364764 Phase 4 Sirolimus
4 A Prospective, Phase IV, Open-Label, Multi-Center Study Evaluating Changes in Bone Marrow Morphology in Adult Subjects Receiving Romiplostim for the Treatment of Thrombocytopenia Associated With Immune (Idiopathic) Thrombocytopenia Purpura (ITP) Completed NCT00907478 Phase 4
5 An Open-label, Prospective, Multicenter Study to Investigate the Specificity of in Vivo Antibody Binding to Red Blood Cells in Subjects With Chronic Immune Thrombocytopenic Purpura (ITP) Treated With IgPro10 (Privigen®) Who Have Shown Signs of Hemolysis Completed NCT01390649 Phase 4
6 High-dose Dexamethasone and Conventional Dose Prednisone, for the First-line Treatment of Adults With ITP: a Multicenter, Randomized Controlled, Clinical Trial Completed NCT01356511 Phase 4 Prednisone;Dexamethasone
7 The Clinical Randomized Controlled Study of Different Dose Rituximab in the Treatment of Primary Immune Thrombocytopenia Completed NCT03258866 Phase 4 Rituximab;Rituximab
8 Helicobacter Pylori Infection in Children With Chronic Idiopathic Thrombocytopenic Purpura Completed NCT00467571 Phase 4 lansoprazole, clarithromycin, amoxycillin
9 Assessment of Platelet Function in Patients With Chronic Autoimmune Thrombocytopenic Purpura (cAITP) Treated With the Thrombopoietin Receptor (MPL) Agonist Eltrombopag. Completed NCT00888901 Phase 4 eltrombopag;corticosteroids (Aprednislon)
10 A Longitudinal 2-year Bone Marrow Study of Eltrombopag Olamine (SB-497115-GR) in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Completed NCT01098487 Phase 4 Eltrombopag olamine
11 Multicenter, Randomized, Open, Parallel Controlled Trials Evaluating the Efficacy and Safety of Different Human Thrombopoietin (rhTPO) Regimens in the Treatment of Patients With Primary Immune Thrombocytopenia (ITP) Completed NCT04089267 Phase 4 TPO
12 Collection of Blood Samples From Patients With Relapsing Forms of Multiple Sclerosis (RMS) Who Have Developed Immune Thrombocytopenic Purpura (ITP) After LEMTRADA® Treatment Completed NCT03784898 Phase 4
13 Thrombopoietin-receptor Agonist-immunomodulation in Young Adult Primary Immune Thrombocytopenia (ITP): A Multi-center Open Label Trial With Romiplostim Completed NCT02760251 Phase 4 romiplostim
14 Reposition of Second Line Treatment in Chronic Immune Thrombocytopenia Completed NCT03229746 Phase 4 Hydroxychloroquine;vincristine;azathioprine
15 A Prospective, Multicenter, Placebo Controlled Study on Caffeic Acid Tablet Combining High-dose Dexamethasone in Management of Adult Primary Immune Thrombocytopenia (ITP) Completed NCT02556814 Phase 4 Caffeic acid tablets;Dexamethasone;placebo
16 A Randomized Trial of Standard vs Half Dose Rabeprazole, Clarithromycin, Metronidazole and Amoxicillin in the Treatment of Helicobacter Pylori Infection Completed NCT01219764 Phase 4 Rabeprazole, metronidazole, Clarithromycin, Amoxicillin
17 Effects of Helicobacter Pylori Eradication Therapy in Children With Chronic Immune Thrombocytopenic Purpura Recruiting NCT03172676 Phase 4 Amoxicillin 50 mg/kg/day in 2 divided doses for 14 days.;Clarithromycin 15 mg/kg/day in 2 divided doses for 14 days.;Proton pump inhibitor 1 mg/kg/day in 2 divided doses 1 month
18 Post-Marketing Study to Evaluate the Efficacy and Safety of PANZYGA in Pediatric Patients With Chronic Immune Thrombocytopenia (ITP) Recruiting NCT03866798 Phase 4
19 A Single-center Prospective Randomized Study of Atorvastatin in the Treatment of Newly Diagnosed Primary Immune Thrombocytopenia (ITP) Recruiting NCT03692754 Phase 4 Atorvastatin 20mg;Atorvastatin 10mg
20 A Single-center Prospective Randomized Study of Glycyrrhetinic Acid Combined With Dexamethasone in the Treatment of Newly Diagnosed Primary Immune Thrombocytopenia (ITP) Recruiting NCT03998982 Phase 4 Glycyrrhetinic Acid;Dexamethasone
21 A Multisite, Randomized, Double-Blind, Placebo-Controlled, and Parallel Study to Evaluate the Efficacy and Safety of Huaiqihuang Granule in Children With Chronic Primary Immune Thrombocytopenia (Qi Yin Deficiency) Recruiting NCT03201848 Phase 4 Placebo;Huaiqihuang Granule
22 Efficacy and Safety of rhTPO and Eltrombopag in the Treatment of Chinese Adults With Primary Immune Thrombocytopenia (ITP):a Multicenter, Double-blind, Randomized, Controlled Trial Recruiting NCT03771378 Phase 4 rhTPO;eltrombopag
23 Treatment With Thrombopoietin Mimetic Plus Immunosuppressive Therapy in Egyptian Patients With Aplastic Anaemia Recruiting NCT03896971 Phase 4 Combination of thrombopoietin mimetic and cyclosporin A
24 Randomized Clinical Trial of the Use of Eltrombopag in Children With Idiopathic Aplastic Anemia Recruiting NCT03243656 Phase 4 Eltrombopag
25 Rate of Prolonged Response After Stopping Thrombopoietin-receptor Agonists Treatment in Immune Thrombocytopenia: a Prospective Multicenter Open Study Recruiting NCT03119974 Phase 4 Tpo-RA discontinuation
26 Study 200170: A Rollover Study to Provide Continued Treatment With Eltrombopag Active, not recruiting NCT01957176 Phase 4 ELT
27 A Long-term Follow-up Study for Multiple Sclerosis Patients Who Have Completed the Alemtuzumab Extension Study (CAMMS03409) Active, not recruiting NCT02255656 Phase 4 alemtuzumab GZ402673
28 Efficacy of Eltrombopag in Chronic Immune Thrombocytopenia in Pediatrics Not yet recruiting NCT04102033 Phase 4 Eltrombopag
29 A Multicenter Randomized Open-label Clinical Trial of Vitamin D Combined With HD-DXM Versus HD-DXM for the Treatment of ITP Not yet recruiting NCT04094805 Phase 4 Rocaltrol;Dexamethasone
30 Dexamethasone Compared to Conventional Therapy in the Treatment of Acute Pericarditis: a Superiority Randomized Controlled Trial (Dexa-P) Not yet recruiting NCT04323280 Phase 4 Dexamethasone therapy;Conventional Therapy
31 Different Cycles of High-dose Dexamethasone for Initial Management of Primary Immune Thrombocytopenia (ITP): a Prospective, Randomized Controlled Trial Withdrawn NCT02642380 Phase 4 Dexamethasone (4 cycles);Dexamethasone (1 cycle)
32 AN OPEN-LABEL TRIAL OF REDUCED- DOSE PYLERA (BISMUTH, METRONIDAZOLE, TETRACYCLINE), AMOXICILLIN, AND ESOMEPRAZOLE IN THE TREATMENT OF HELICOBACTER PYLORI INFECTION Withdrawn NCT02045251 Phase 4 Pylera based reduced regimen
33 Association of FC Gamma RIIIA Polymorphism and Thrombopoietin (THPO) Expression With Response to TPO Agonists in Refractory ITP and the Impact of Therapy on B and T Cells Subsets in the Patients With Mutated Genotypes Unknown status NCT02877212 Phase 3 Eltrombopag
34 A Multicenter, Open-Label, Phase III Study to Evaluate the Efficacy and Safety of LIV-GAMMA SN Inj. in Primary Immune Thrombocytopenia (ITP) Unknown status NCT03164915 Phase 3
35 Thrombocytopenia in Gestational Period Unknown status NCT02751593 Phase 2, Phase 3 Dexamethasone
36 Evaluation of Oxidant Status in Patients With Immune Thrombocytopenia (ITP) and the Role of an Adjuvant Antioxidant Therapy Unknown status NCT01763658 Phase 2, Phase 3 Antox tablets(Mepaco)
37 Recombinant Human Thrombopoietin (rhTPO) in Management of Immune Thrombocytopenia (ITP)in Pregnancy: a Single-center Clinical Trial Unknown status NCT02270801 Phase 3 rhTPO
38 A Multicenter Randomized Study of Dexamethasone Combined With Rituximab, Cyclosporin and Intravenous Immunoglobulin in the Management of Newly Diagnosed ITP Patients Unknown status NCT02834468 Phase 3 DEX Combined With RTX, CSA and IVIG
39 A Multicenter, Single-Arm, Open Label Study Evaluating the Efficacy and Safety of Maintenance Treatment With Recombinant Human Thrombopoietin in Thrombocytopenic Subjects With Immune Thrombocytopenia Unknown status NCT01805648 Phase 3 rhTPO
40 Prospective Multicenter Randomized Open-label Controlled Trial Assessing Efficacy and Safety of DAPSone as a Second-line Option in Adult Immune Thrombocytopenia Unknown status NCT02627417 Phase 3 Dapsone (Disulone®);Prednisone (Cortancyl®) alone followed by monitoring and "standard of care";Prednisone (Cortancyl®)
41 Proof of Concept; A Pilot, Randomized, Double-Blind Study of Oseltamivir Versus Placebo for Immune Thrombocytopenia Unknown status NCT03520049 Phase 3 Oseltamivir;Placebo
42 Randomized, Placebo-Controlled, Double-Blind Clinical Trial to Evaluate the Safety and Efficacy of Low-Dose Glucocorticoid Infusion in Acute Respiratory Distress Syndrome (ARDS) Unknown status NCT00562835 Phase 2, Phase 3 Methylprednisolone
43 An Open-label, Multicenter Study on the Efficacy and Safety of IgPro10 in Patients With Chronic Immune Thrombocytopenic Purpura (ITP) Completed NCT00168038 Phase 3
44 A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura Completed NCT02076399 Phase 3 Fostamatinib disodium;Placebo
45 Rituximab as Second Line Treatment for ITP; A Multicenter, Randomized, Double Blind, Placebo-controlled, Phase III Study. "The RITP Study" Completed NCT00344149 Phase 3 Rituximab (Mabthera)
46 A Clinical Investigation to Assess the Safety and Efficacy of Immune Globulin Intravenous (Human), 10% in Subjects With Primary Immunodeficiency Disorders Completed NCT00157079 Phase 3
47 A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura Completed NCT02076412 Phase 3 Fostamatinib Disodium;Placebo
48 A Multi-center, Prospective, Open-label, Clinical Trial to Assess the Safety and the Efficacy of a New Intravenous Immune Globulin (IGIV3I Grifols 10%) in Patients With Idiopathic (Immune) Thrombocytopenic Purpura Completed NCT00511147 Phase 3
49 A Two Part, Double-blind, Randomized, Placebo-controlled and Open-label Study to Investigate the Efficacy, Safety and Tolerability of Eltrombopag, a Thrombopoietin Receptor Agonist, in Pediatric Patients With Previously Treated Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP). PETIT2: Eltrombopag in PEdiatric Patients With Thrombocytopenia From ITP Completed NCT01520909 Phase 3 Eltrombopag;Placebo
50 Randomized Study of the Treatment of Primary Immune Thrombocytopenic Purpura (ITP) in Newly Diagnosed Untreated Adult Patients. Comparison of Standard Dose Prednisone Versus High-dose Dexamethasone. Completed NCT00657410 Phase 3 dexamethasone;prednisone

Search NIH Clinical Center for Thrombocytopenic Purpura, Autoimmune

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Azathioprine
Cyclophosphamide
Immunoglobulins, Intravenous
Intramuscular immunoglobulin
Rho(D) Immune Globulin, human
Venoglobulin-I
Vinblastine
Vinblastine Sulfate

Cochrane evidence based reviews: purpura, thrombocytopenic, idiopathic

Genetic Tests for Thrombocytopenic Purpura, Autoimmune

Anatomical Context for Thrombocytopenic Purpura, Autoimmune

MalaCards organs/tissues related to Thrombocytopenic Purpura, Autoimmune:

40
Bone, Bone Marrow, Spleen, T Cells, B Cells, Testes, Liver

Publications for Thrombocytopenic Purpura, Autoimmune

Articles related to Thrombocytopenic Purpura, Autoimmune:

(show top 50) (show all 4438)
# Title Authors PMID Year
1
Copy number variation of the activating FCGR2C gene predisposes to idiopathic thrombocytopenic purpura. 61 56
17827395 2008
2
Is eradication therapy useful as the first line of treatment in Helicobacter pylori-positive idiopathic thrombocytopenic purpura? Analysis of 207 eradicated chronic ITP cases in Japan. 56 61
15765787 2005
3
Historical aspects and present knowledge of idiopathic thrombocytopenic purpura. 61 56
12472565 2002
4
Chronic idiopathic thrombocytopenic purpura. 61 56
7935660 1994
5
Idiopathic thrombocytopenic purpura in two elderly siblings. 56 61
4074042 1985
6
Helicobacter pylori eradication shifts monocyte Fcgamma receptor balance toward inhibitory FcgammaRIIB in immune thrombocytopenic purpura patients. 56
18654664 2008
7
Immune thrombocytopenic purpura. 56
11919310 2002
8
Regression of autoimmune thrombocytopenia after eradication of Helicobacter pylori. 56
9742983 1998
9
Autoimmune thrombocytopenic purpura. 56
2413550 1985
10
Chronic immune thrombocytopenic purpura in monozygotic twins: genetic factors predisposing to ITP. 56
6890627 1982
11
Specificity of autoantibodies in autoimmune thrombocytopenia. 56
7032627 1982
12
Hereditary autoimmune thrombocytopenic purpura: an immunologic and genetic study. 56
7195175 1981
13
Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura. 56
14850832 1951
14
Review article: second-generation thrombopoietin agents for treatment of chronic idiopathic thrombocytopenic purpura in adults. 54 61
19525300 2010
15
[Expression of T-bet and GATA3 in children with acute idiopathic thrombocytopenic purpura]. 54 61
20113630 2010
16
High-dose dexamethasone regulates interleukin-18 and interleukin-18 binding protein in idiopathic thrombocytopenic purpura. 61 54
19797730 2009
17
New treatments for idiopathic thrombocytopenic purpura: rethinking old hypotheses. 61 54
19426124 2009
18
Interleukin 18 and interleukin 18 binding protein in patients with idiopathic thrombocytopenic purpura. 54 61
19077159 2009
19
Romiplostim. 54 61
19275274 2009
20
Single nucleotide polymorphism in DNMT3B promoter and the risk for idiopathic thrombocytopenic purpura in Chinese population. 61 54
18437543 2008
21
[Expression of co-stimulatory molecules and role of interleukin 18 in peripheral lymphocytes of patients with idiopathic thrombocytopenic purpura]. 54 61
17605869 2007
22
Immune response to CagA protein is associated with improved platelet count after Helicobacter pylori eradication in patients with idiopathic thrombocytopenic purpura. 54 61
17241299 2007
23
Prolonged thrombocytopenia after allogeneic hematopoietic stem cell transplantation: associations with impaired platelet production and increased platelet turnover. 54 61
16915226 2006
24
Novel heterozygous missense mutation in the second leucine rich repeat of GPIbalpha affects GPIb/IX/V expression and results in macrothrombocytopenia in a patient initially misdiagnosed with idiopathic thrombocytopenic purpura. 54 61
16519708 2006
25
[Curative effect of interleukin 11 on chronic idiopathic thrombocytopenic purpura]. 54 61
16584619 2006
26
Multiple cycles of recombinant human thrombopoietin therapy in a patient with chronic refractory idiopathic thrombocytopenic purpura. 54 61
15870550 2005
27
Increased glycocalicin index and normal thrombopoietin levels in patients with idiopathic thrombocytopenic purpura with a decreased rate of platelet production. 54 61
15921398 2005
28
Danazol, idiopathic thrombocytopenic purpura, and thrombopoietin. 61 54
15629743 2004
29
Anti-GPVI-associated ITP: an acquired platelet disorder caused by autoantibody-mediated clearance of the GPVI/FcRgamma-chain complex from the human platelet surface. 61 54
15150079 2004
30
[A multi-center clinical trial of recombinant human thrombopoietin in chronic refractory idiopathic thrombocytopenic purpura]. 61 54
15355668 2004
31
Molecular mimicry by Helicobacter pylori CagA protein may be involved in the pathogenesis of H. pylori-associated chronic idiopathic thrombocytopenic purpura. 61 54
14675413 2004
32
[Interleukin-18 and its related cytokines in plasma of patients with idiopathic thrombocytopenic purpura]. 61 54
14706156 2003
33
Soluble P-selectin, interleukin 6, and thrombopoietin levels in children with acute and chronic idiopathic thrombocytopenic purpura and their relationship with mega-dose methylprednisolone therapy: a pilot study. 61 54
12468916 2002
34
Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. 61 54
12411315 2002
35
Autoantibody to c-Mpl (thrombopoietin receptor) in systemic lupus erythematosus: relationship to thrombocytopenia with megakaryocytic hypoplasia. 54 61
12209520 2002
36
[Study on the relations between HLA-DRB1 alleles and idiopathic thrombocytopenic purpura in children]. 61 54
12170464 2002
37
Plasma thrombopoietin levels in patients with aplastic anemia and idiopathic thrombocytopenic purpura. 61 54
12150725 2002
38
The potential role of thrombopoietin in idiopathic thrombocytopenic purpura. 54 61
11913997 2002
39
[The effects of thrombopoietin and interleukin-11 on bone marrow megakaryocytic progenitors in patients with chronic idiopathic thrombocytopenic purpura in vitro]. 54 61
12528552 2001
40
[The relativity study of thrombopoietin and chronic idiopathic thrombocytopenic purpura]. 54 61
11758228 2001
41
Colony-forming unit-megakaryocyte (CFR-meg) numbers and serum thrombopoietin concentrations in thrombocytopenic disorders: an inverse correlation in myelodysplastic syndromes. 61 54
11021750 2000
42
[Clinical study on interferon treatment of chronic idiopathic thrombocytopenic purpura]. 61 54
12545843 2000
43
[The sensitivity, specificity and predictive value of PAIgG, reticulated platelets, thrombopoietin levels, and platelet size for the differential diagnosis of thrombocytopenia]. 54 61
10624125 1999
44
Serum levels of thrombopoietin, IL-11, and IL-6 in pediatric thrombocytopenias. 61 54
10525827 1999
45
Systemic causes of excessive uterine bleeding. 54 61
10513767 1999
46
Concentrations of thrombopoietin in bone marrow in normal subjects and in patients with idiopathic thrombocytopenic purpura, aplastic anemia, and essential thrombocythemia correlate with its mRNA expression of bone marrow stromal cells. 61 54
9639498 1998
47
Plasma thrombopoietin levels in thrombocytopenic states: implication for a regulatory role of bone marrow megakaryocytes. 61 54
9633881 1998
48
Increased thrombopoietin levels in idiopathic thrombocytopenic purpura patients with a poor response to steroid therapy. 61 54
9690802 1998
49
Evaluation of thrombopoiesis in thrombocytopenic disorders by simultaneous measurement of reticulated platelets of whole blood and serum thrombopoietin concentrations. 54 61
9657432 1998
50
Blood thrombopoietin, IL-6 and IL-11 levels in patients with agnogenic myeloid metaplasia. 61 54
9369414 1997

Variations for Thrombocytopenic Purpura, Autoimmune

Copy number variations for Thrombocytopenic Purpura, Autoimmune from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 21699 1 160500000 165500000 Copy number FCGR2C Idiopathic thrombocytopenic purpura
2 46119 10 77700000 82000000 Copy number BMPR1A Idiopathic thrombocytopenic purpura
3 121460 18 43500000 48200000 Copy number MADH4 Idiopathic thrombocytopenic purpura

Expression for Thrombocytopenic Purpura, Autoimmune

Search GEO for disease gene expression data for Thrombocytopenic Purpura, Autoimmune.

Pathways for Thrombocytopenic Purpura, Autoimmune

Pathways related to Thrombocytopenic Purpura, Autoimmune according to KEGG:

36
# Name Kegg Source Accession
1 Phagosome hsa04145
2 Osteoclast differentiation hsa04380
3 Fc gamma R-mediated phagocytosis hsa04666

Pathways related to Thrombocytopenic Purpura, Autoimmune according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.19 ITGB3 ITGA2B IL18 IL11 IFNA2 GATA3
2
Show member pathways
13.07 THPO SELP MPL ITGB3 ITGA2B IFNA2
3
Show member pathways
12 ITGB3 ITGA2B GP6 GP5 GP1BA
4
Show member pathways
11.98 GP6 GP5 GP1BA F8
5 11.81 ITGB3 ITGA2B GP6 GP5 GP1BA
6 11.63 THPO ITGB3 ITGA2B IL11 GP5 GP1BA
7 11.49 SELP ITGB3 CD40LG
8
Show member pathways
11.42 THPO MPL ITGB3 ITGA2B GP5 GP1BA
9 11.38 ITGB3 ITGA2B GP6 GP5
10 11.37 SELP IL18 CD40LG
11 11.29 THPO MPL ITGB3 ITGA2B IL11 IFNA2
12 10.84 THPO ITGB3 ITGA2B IL18 IL11 CD40LG
13 10.72 GP6 GP5 GP1BA
14 10.52 GP5 GP1BA

GO Terms for Thrombocytopenic Purpura, Autoimmune

Cellular components related to Thrombocytopenic Purpura, Autoimmune according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.86 SELP RHD ITGB3 GP6 GP5 GP1BA
2 extracellular space GO:0005615 9.81 THPO SELP S100A8 IL18 IL11 IFNA2
3 cell surface GO:0009986 9.8 MPL ITGB3 ITGA2B GP6 GP1BA CD40LG
4 plasma membrane GO:0005886 9.8 SELP S100A8 RHD MPL LRBA ITGB3
5 platelet alpha granule membrane GO:0031092 8.8 SELP ITGB3 ITGA2B

Biological processes related to Thrombocytopenic Purpura, Autoimmune according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.85 SELP S100A8 IL18 IFNA2 CD40LG
2 cytokine-mediated signaling pathway GO:0019221 9.8 MPL IL18 IL11 IFNA2 GATA3
3 integrin-mediated signaling pathway GO:0007229 9.69 ITGB3 ITGA2B CD40LG
4 platelet degranulation GO:0002576 9.67 SELP ITGB3 ITGA2B F8
5 B cell differentiation GO:0030183 9.65 IL11 IFNA2 CD40LG
6 hemostasis GO:0007599 9.56 GP6 GP5 GP1BA F8
7 blood coagulation, intrinsic pathway GO:0007597 9.5 GP5 GP1BA F8
8 positive regulation of leukocyte migration GO:0002687 9.49 SELP ITGA2B
9 platelet aggregation GO:0070527 9.46 MPL ITGB3 ITGA2B GP1BA
10 thrombopoietin-mediated signaling pathway GO:0038163 9.43 THPO MPL
11 platelet activation GO:0030168 9.43 ITGB3 GP6 GP5 GP1BA F8 CD40LG
12 blood coagulation GO:0007596 9.17 ITGB3 IFNA2 GP6 GP5 GP1BA GATA3

Molecular functions related to Thrombocytopenic Purpura, Autoimmune according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.11 SELP S100A8 MPL LRBA ITGB3 ITGA2B
2 cytokine activity GO:0005125 9.02 THPO IL18 IL11 IFNA2 CD40LG
3 fibrinogen binding GO:0070051 8.96 ITGB3 ITGA2B

Sources for Thrombocytopenic Purpura, Autoimmune

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....